Cargando…

Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses

BACKGROUND: As a risk-mitigation strategy to minimize paralytic polio following withdrawal of Sabin type 2 from the oral poliovirus vaccine in April 2016, a single full dose or 2 fractional doses of inactivated poliovirus vaccine (IPV) are recommended. However, limited knowledge exists on long-term...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhaumik, Siddhartha Kumar, Kulkarni, Raveendra R, Weldon, William C, Silveira, Eduardo L V, Ahmed, Hasan, Gunisetty, Sivaram, Chandele, Anmol, Antia, Rustom, Verma, Harish, Sutter, Roland, Pallansch, Mark A, Oberste, M Steven, Villinger, Francois, Orenstein, Walter, Murali-Krishna, Kaja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206122/
https://www.ncbi.nlm.nih.gov/pubmed/30376091
http://dx.doi.org/10.1093/cid/ciy634
_version_ 1783366305544404992
author Bhaumik, Siddhartha Kumar
Kulkarni, Raveendra R
Weldon, William C
Silveira, Eduardo L V
Ahmed, Hasan
Gunisetty, Sivaram
Chandele, Anmol
Antia, Rustom
Verma, Harish
Sutter, Roland
Pallansch, Mark A
Oberste, M Steven
Villinger, Francois
Orenstein, Walter
Murali-Krishna, Kaja
author_facet Bhaumik, Siddhartha Kumar
Kulkarni, Raveendra R
Weldon, William C
Silveira, Eduardo L V
Ahmed, Hasan
Gunisetty, Sivaram
Chandele, Anmol
Antia, Rustom
Verma, Harish
Sutter, Roland
Pallansch, Mark A
Oberste, M Steven
Villinger, Francois
Orenstein, Walter
Murali-Krishna, Kaja
author_sort Bhaumik, Siddhartha Kumar
collection PubMed
description BACKGROUND: As a risk-mitigation strategy to minimize paralytic polio following withdrawal of Sabin type 2 from the oral poliovirus vaccine in April 2016, a single full dose or 2 fractional doses of inactivated poliovirus vaccine (IPV) are recommended. However, limited knowledge exists on long-term persistence of immune memory following 1- or 2-dose IPV schedules. METHODS: We examined induction and maintenance of immune memory following single- vs 2-dose IPV schedules, either full-dose intramuscular or fractional-dose intradermal, in rhesus macaques. Humoral responses, bone marrow–homing antibody-secreting plasma cells, and blood-circulating/lymph node–homing memory B cells were examined longitudinally. RESULTS: A single dose of IPV, either full or fractional, induced binding antibodies and memory B cells in all vaccinated macaques, despite failing to induce neutralizing antibodies (NT Abs) in many of them. However, these memory B cells declined rapidly, reaching below detection in the systemic circulation by 5 months; although a low frequency of memory B cells was detectable in draining lymph nodes of some, but not all, animals. By contrast, a 2-dose vaccination schedule, either full or fractional, efficiently induced NT Abs in all animals along with bone marrow–homing plasma cells and memory B cells. These memory B cells persisted in the systemic circulation for up to 16 months, the maximum duration tested after the second dose of vaccination. CONCLUSIONS: Two doses of IPV, regardless of whether fractional or full, are more effective than a single dose for inducing long-lasting memory B cells.
format Online
Article
Text
id pubmed-6206122
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62061222018-11-02 Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses Bhaumik, Siddhartha Kumar Kulkarni, Raveendra R Weldon, William C Silveira, Eduardo L V Ahmed, Hasan Gunisetty, Sivaram Chandele, Anmol Antia, Rustom Verma, Harish Sutter, Roland Pallansch, Mark A Oberste, M Steven Villinger, Francois Orenstein, Walter Murali-Krishna, Kaja Clin Infect Dis Supplement Articles BACKGROUND: As a risk-mitigation strategy to minimize paralytic polio following withdrawal of Sabin type 2 from the oral poliovirus vaccine in April 2016, a single full dose or 2 fractional doses of inactivated poliovirus vaccine (IPV) are recommended. However, limited knowledge exists on long-term persistence of immune memory following 1- or 2-dose IPV schedules. METHODS: We examined induction and maintenance of immune memory following single- vs 2-dose IPV schedules, either full-dose intramuscular or fractional-dose intradermal, in rhesus macaques. Humoral responses, bone marrow–homing antibody-secreting plasma cells, and blood-circulating/lymph node–homing memory B cells were examined longitudinally. RESULTS: A single dose of IPV, either full or fractional, induced binding antibodies and memory B cells in all vaccinated macaques, despite failing to induce neutralizing antibodies (NT Abs) in many of them. However, these memory B cells declined rapidly, reaching below detection in the systemic circulation by 5 months; although a low frequency of memory B cells was detectable in draining lymph nodes of some, but not all, animals. By contrast, a 2-dose vaccination schedule, either full or fractional, efficiently induced NT Abs in all animals along with bone marrow–homing plasma cells and memory B cells. These memory B cells persisted in the systemic circulation for up to 16 months, the maximum duration tested after the second dose of vaccination. CONCLUSIONS: Two doses of IPV, regardless of whether fractional or full, are more effective than a single dose for inducing long-lasting memory B cells. Oxford University Press 2018-11-15 2018-10-30 /pmc/articles/PMC6206122/ /pubmed/30376091 http://dx.doi.org/10.1093/cid/ciy634 Text en © The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Articles
Bhaumik, Siddhartha Kumar
Kulkarni, Raveendra R
Weldon, William C
Silveira, Eduardo L V
Ahmed, Hasan
Gunisetty, Sivaram
Chandele, Anmol
Antia, Rustom
Verma, Harish
Sutter, Roland
Pallansch, Mark A
Oberste, M Steven
Villinger, Francois
Orenstein, Walter
Murali-Krishna, Kaja
Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses
title Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses
title_full Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses
title_fullStr Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses
title_full_unstemmed Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses
title_short Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses
title_sort immune priming and long-term persistence of memory b cells after inactivated poliovirus vaccine in macaque models: support for at least 2 doses
topic Supplement Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206122/
https://www.ncbi.nlm.nih.gov/pubmed/30376091
http://dx.doi.org/10.1093/cid/ciy634
work_keys_str_mv AT bhaumiksiddharthakumar immuneprimingandlongtermpersistenceofmemorybcellsafterinactivatedpoliovirusvaccineinmacaquemodelssupportforatleast2doses
AT kulkarniraveendrar immuneprimingandlongtermpersistenceofmemorybcellsafterinactivatedpoliovirusvaccineinmacaquemodelssupportforatleast2doses
AT weldonwilliamc immuneprimingandlongtermpersistenceofmemorybcellsafterinactivatedpoliovirusvaccineinmacaquemodelssupportforatleast2doses
AT silveiraeduardolv immuneprimingandlongtermpersistenceofmemorybcellsafterinactivatedpoliovirusvaccineinmacaquemodelssupportforatleast2doses
AT ahmedhasan immuneprimingandlongtermpersistenceofmemorybcellsafterinactivatedpoliovirusvaccineinmacaquemodelssupportforatleast2doses
AT gunisettysivaram immuneprimingandlongtermpersistenceofmemorybcellsafterinactivatedpoliovirusvaccineinmacaquemodelssupportforatleast2doses
AT chandeleanmol immuneprimingandlongtermpersistenceofmemorybcellsafterinactivatedpoliovirusvaccineinmacaquemodelssupportforatleast2doses
AT antiarustom immuneprimingandlongtermpersistenceofmemorybcellsafterinactivatedpoliovirusvaccineinmacaquemodelssupportforatleast2doses
AT vermaharish immuneprimingandlongtermpersistenceofmemorybcellsafterinactivatedpoliovirusvaccineinmacaquemodelssupportforatleast2doses
AT sutterroland immuneprimingandlongtermpersistenceofmemorybcellsafterinactivatedpoliovirusvaccineinmacaquemodelssupportforatleast2doses
AT pallanschmarka immuneprimingandlongtermpersistenceofmemorybcellsafterinactivatedpoliovirusvaccineinmacaquemodelssupportforatleast2doses
AT oberstemsteven immuneprimingandlongtermpersistenceofmemorybcellsafterinactivatedpoliovirusvaccineinmacaquemodelssupportforatleast2doses
AT villingerfrancois immuneprimingandlongtermpersistenceofmemorybcellsafterinactivatedpoliovirusvaccineinmacaquemodelssupportforatleast2doses
AT orensteinwalter immuneprimingandlongtermpersistenceofmemorybcellsafterinactivatedpoliovirusvaccineinmacaquemodelssupportforatleast2doses
AT muralikrishnakaja immuneprimingandlongtermpersistenceofmemorybcellsafterinactivatedpoliovirusvaccineinmacaquemodelssupportforatleast2doses